{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T06:53:06Z","timestamp":1761893586534},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2002,1,1]],"date-time":"2002-01-01T00:00:00Z","timestamp":1009843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2002,1,1]],"date-time":"2002-01-01T00:00:00Z","timestamp":1009843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"published-print":{"date-parts":[[2002,1,1]]},"DOI":"10.1038\/sj.jhh.1001299","type":"journal-article","created":{"date-parts":[[2002,9,5]],"date-time":"2002-09-05T18:38:32Z","timestamp":1031251112000},"page":"13-19","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by \u03b2-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial"],"prefix":"10.1038","volume":"16","author":[{"given":"J J","family":"Sramek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M T","family":"Leibowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S P","family":"Weinstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E D","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C M","family":"Mendel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F G","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W S","family":"Mullican","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P D","family":"Toth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N R","family":"Cutler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2002,3,1]]},"reference":[{"key":"BF1001299_CR1","doi-asserted-by":"crossref","unstructured":"Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Arch Intern Med 1997 157: 2413\u20132446","DOI":"10.1001\/archinte.157.21.2413"},{"key":"BF1001299_CR2","doi-asserted-by":"crossref","unstructured":"Guidelines Subcommittee of the World Health Organization-International Society of Hypertension Mild Hypertension Liaison Committee. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension J Hypertens 1999 17: 151\u2013183","DOI":"10.1097\/00004872-199917020-00001"},{"key":"BF1001299_CR3","doi-asserted-by":"crossref","unstructured":"National Task Force on the Prevention and Treatment of Obesity. Long-term pharmacotherapy in the management of obesity JAMA 1996 276: 1907\u20131915","DOI":"10.1001\/jama.276.23.1907"},{"key":"BF1001299_CR4","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1046\/j.1463-1326.2000.00071.x","volume":"2","author":"N Finer","year":"2000","unstructured":"Finer N et al. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study Diabetes, Obes Metab 2000 2: 105\u2013112","journal-title":"Diabetes, Obes Metab"},{"key":"BF1001299_CR5","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1046\/j.1463-1326.2000.00081.x","volume":"2","author":"K Fujioka","year":"2000","unstructured":"Fujioka K et al. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obesepatients with type 2 diabetes mellitus Diabetes, Obes Metab 2000 2: 175\u2013187","journal-title":"Diabetes, Obes Metab"},{"key":"BF1001299_CR6","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0002-9343(98)00411-2","volume":"106","author":"M Apfelbaum","year":"1999","unstructured":"Apfelbaum M et al. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine Am J Med 1999 106: 179\u2013184","journal-title":"Am J Med"},{"key":"BF1001299_CR7","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/j.1550-8528.1996.tb00544.x","volume":"4","author":"GA Bray","year":"1996","unstructured":"Bray GA et al. A double-blind randomized placebo-controlled trial of sibutramine Obes Res 1996 4: 263\u2013270","journal-title":"Obes Res"},{"key":"BF1001299_CR8","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1345\/aph.18319","volume":"33","author":"CA Luque","year":"1999","unstructured":"Luque CA, Rey JA . Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity Ann Pharmacother 1999 33: 968\u2013978","journal-title":"Ann Pharmacother"},{"key":"BF1001299_CR9","first-page":"581","volume":"283","author":"C Gundlah","year":"1997","unstructured":"Gundlah C, Martin KF, Heal DJ, Auerbach SB . In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: sibutramine is a reuptake inhibitor J Pharmacol Exp ther 1997 283: 581\u2013591","journal-title":"J Pharmacol Exp ther"},{"key":"BF1001299_CR10","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/00004714-199806000-00008","volume":"18","author":"JO Cole","year":"1998","unstructured":"Cole JO et al. Sibutramine: a new weight loss agent without evidence of the abuse potential associated with amphetamines J Clin Psychopharmacol 1998 18: 231\u2013236","journal-title":"J Clin Psychopharmacol"},{"key":"BF1001299_CR11","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s002130050001","volume":"147","author":"LM Schuh","year":"2000","unstructured":"Schuh LM, Schuster CR, Hopper JA, Mendel CM . Abuse liability assessment of sibutramine, a novel weight control agent Psychopharmacology 2000 147: 339\u2013346","journal-title":"Psychopharmacology"},{"key":"BF1001299_CR12","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/j.1550-8528.1999.tb00419.x","volume":"7","author":"DS Bach","year":"1999","unstructured":"Bach DS et al. Absence of cardiac valve dysfunction in obesepatients treated with sibutramine Obes Res 1999 7: 363\u2013369","journal-title":"Obes Res"},{"key":"BF1001299_CR13","unstructured":"US Department of Health and Human Services. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: US Department of Health and Human Services Interim Public Health Recommendations, November 1997 MMWR Morb Mortal Wkly Rep 1997 46: 1061\u20131066"},{"key":"BF1001299_CR14","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/BF02245152","volume":"107","author":"DJ Heal","year":"1992","unstructured":"Heal DJ et al. A comparison of the effects of sibutramine hydrochloride, bupropion and methamphetamine on dopaminergic function: evidence that dopamine is not a pharmacological target for sibutramine Psychopharmacology (Berl) 1992 107: 303\u2013309","journal-title":"Psychopharmacology (Berl)"},{"key":"BF1001299_CR15","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/j.1550-8528.1999.tb00701.x","volume":"7","author":"GA Bray","year":"1999","unstructured":"Bray GA et al. Sibutramine produces dose-related weight loss Obes Res 1999 7: 189\u2013198","journal-title":"Obes Res"},{"key":"BF1001299_CR16","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/sj.ijo.0801098","volume":"24","author":"G Fangh\u00e4nel","year":"2000","unstructured":"Fangh\u00e4nel G, Cortinas L, S\u00e1nchez-Reyes L, Berber A . A clinical trial of the use of sibutramine for the treatment ofpatients suffering essential obesity Int J Obes Relat Metab Disord 2000 24: 144\u2013150","journal-title":"Int J Obes Relat Metab Disord"},{"key":"BF1001299_CR17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/oby.2000.10","volume":"8","author":"GEM Cuellar","year":"2000","unstructured":"Cuellar GEM, Ruiz AM, Monsalve MCR, Berber A . Six-month treatment of obesity with sibutramine 15\u2009mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population Obes Res 2000 8: 71\u201382","journal-title":"Obes Res"},{"key":"BF1001299_CR18","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1177\/009286159703100112","volume":"31","author":"C Fizames","year":"1997","unstructured":"Fizames C . How to improve the medical quality of the coding reports based on WHO-ART and COSTART use Drug Information J 1997 31: 85\u201392","journal-title":"Drug Information J"},{"key":"BF1001299_CR19","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1093\/ajcn\/68.6.1180","volume":"68","author":"DL Hansen","year":"1998","unstructured":"Hansen DL et al. Thermogenic effects of sibutramine in humans Am J Clin Nutr 1998 68: 1180\u20131186","journal-title":"Am J Clin Nutr"},{"key":"BF1001299_CR20","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1038\/sj.ijo.0801045","volume":"23","author":"KM Walsh","year":"1999","unstructured":"Walsh KM, Leen E, Lean MEJ . The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females Int J Obes Relat Metab Disord 1999 23: 1009\u20131015","journal-title":"Int J Obes Relat Metab Disord"},{"key":"BF1001299_CR21","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0022-2275(20)37695-1","volume":"34","author":"M Lafontan","year":"1993","unstructured":"Lafontan M, Berlan M . Fat cell adrenergic receptors and the control of white and brown fat cell function J Lipid Res 1993 34: 1057\u20131091","journal-title":"J Lipid Res"},{"key":"BF1001299_CR22","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/j.1550-8528.1998.tb00324.x","volume":"6","author":"HM Seagle","year":"1998","unstructured":"Seagle HM, Bessesen DH, Hill JO . Effects of sibutramine on resting metabolic rate and weight loss in overweight women Obes Res 1998 6: 115\u2013121","journal-title":"Obes Res"},{"key":"BF1001299_CR23","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1159\/000026389","volume":"6","author":"KP Mayfield","year":"1999","unstructured":"Mayfield KP et al. Beta-adrenergic receptor subtype effects on stress fever and thermoregulation Neuroimmunomodulation 1999 6: 305\u2013317","journal-title":"Neuroimmunomodulation"},{"key":"BF1001299_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1053\/euhj.1998.1121","volume":"20","author":"JA Staessen","year":"1999","unstructured":"Staessen JA, Wang JG, Birkenhager WH, Fagard R . Treatment with beta-blockers for the primary prevention of the cardiovascular complications of hypertension Eur Heart J 1999 20: 11\u201325","journal-title":"Eur Heart J"},{"key":"BF1001299_CR25","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/oby.2000.26","volume":"8","author":"J Hirsch","year":"2000","unstructured":"Hirsch J, Mackintosh RM, Aronne LJ . The effects of drugs used to treat obesity on the autonomic nervous system Obes Res 2000 8: 227\u2013233","journal-title":"Obes Res"},{"key":"BF1001299_CR26","unstructured":"Meridia\u00ae (sibutramine hydrochloride monohydrate) capsules. In: Physicians\u2019 Desk Reference Medical Economics Company, Inc: Montvale, NJ 2000 pp 1494\u20131498"},{"key":"BF1001299_CR27","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1161\/01.CIR.96.9.3248","volume":"96","author":"RH Eckel","year":"1997","unstructured":"Eckel RH for the Nutrition Committee. Obesity in heart disease. A statement for healthcare professionals from the Nutrition Committee, American Heart Association Circulation 1997 96: 3248\u20133250","journal-title":"Circulation"},{"key":"BF1001299_CR28","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/clpt.1991.144","volume":"50","author":"M Weintraub","year":"1991","unstructured":"Weintraub M et al. Sibutramine in weight control: a dose-ranging, efficacy study Clin Pharmacol Ther 1991 50: 330\u2013337","journal-title":"Clin Pharmacol Ther"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/1001299.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1001299","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1001299.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T14:28:06Z","timestamp":1647527286000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1001299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,1,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2002,1,1]]}},"alternative-id":["BF1001299"],"URL":"https:\/\/doi.org\/10.1038\/sj.jhh.1001299","relation":{},"ISSN":["0950-9240","1476-5527"],"issn-type":[{"value":"0950-9240","type":"print"},{"value":"1476-5527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,1,1]]},"assertion":[{"value":"1 March 2002","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}